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Introduction: Ayurvedic medications consist of herbs that may be intentionally combined with metals, such as
lead, mercury, iron, and zinc. Ayurvedic practitioners and their patients believe that the toxic properties of the
metals are reduced or eliminated during preparation and processing.
Case report: A 69 year old Caucasian male retired professional with a prior history of stroke presented for
evaluation of new onset depression, fatigue, generalized weakness, constipation, anorexia, and weight loss. History
revealed that his symptoms were temporally related to initiation of an Ayurvedic herbal medication. The patient
had been previously admitted to another hospital for these symptoms and was found to have a severe anemia for
which no etiology was found. Laboratory tests revealed an elevated blood lead level and a diagnosis of
symptomatic lead toxicity was made. The patient was treated with intramuscular, intravenous, and oral chelation
therapy to promote lead excretion. Because of complaints of continued poor mental function, neuropsychological
tests were administered before and after one of the chelation treatments and showed improvement in measures of
attention and other cognitive domains. In addition, the patient was able to discontinue use of antidepressant
medication after chelation.
Discussion: A high index of suspicion of metal toxicity is necessary among persons with characteristic symptoms
and signs in the absence of occupational exposure. Despite limited evidence for chelation in adults and in those
with modest blood lead levels, this patient appeared to benefit from repeated chelation therapy. Both allopathic
and alternative medicine practitioners and public health specialists need to be aware of the potential for
contamination of and side effects from alternative pharmacologic and herbal therapies.
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Ayurvedic medicines consist of herbs that are often
intentionally combined with metals, such as lead, mercury,
iron, and zinc, due to the belief that these metals contrib-
ute to their therapeutic effect [1]. Several studies have
shown that approximately 20% of the Ayurvedic supple-
ments (of both US and Indian origin) contain potentially
toxic concentrations of several toxic metals [1,2]. These
studies included supplements purchased via the internet
[1] as well as supplements sold in stores in the U.S. [2].
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reproduction in any medium, provided the orAyurvedic practitioners believe can purify the heavy metals,
thereby eliminating their toxicity prior to consumption by
humans [3]. Contrary to this belief, symptomatic lead tox-
icity following use of Ayurvedic medications has been
reported repeatedly [4-6].
Results of a World Health Organization survey indicated
that about 70-80% of the world populations rely on non-
allopathic or traditional medicines, mainly of herbal
sources, in their healthcare [5]. This widespread use of
herbal medications, combined with the fact that many
cases of lead toxicity may not be recognized clinically,
makes contamination of such herbal medication with
metals and other toxicants a serious global public health
concern. Practitioners providing services to populations
using non-conventional medicines should have a high
index of suspicion of metal toxicity when confronted with
one or more known adverse effects of metal ingestion.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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unnecessary and invasive evaluations are performed.
Contributing to the failure to consider environmental
sources of lead exposure is the fact that 95% of recognized
adult lead toxicity is of occupational origin [7]. Other en-
vironmental sources of adult lead exposure include leaded
gasoline (outside of the US), close proximity to lead emit-
ting industries, home renovation, and numerous hobbies,
including indoor shooting, use of lead containing solders,
and lead containing ceramic glazes [8]. For the patient
presented here, unnecessary tests and a lengthy delay in
treatment could have been avoided if the initial treating cli-
nicians had obtained a more complete environmental his-
tory including use of alternative medications and therapies.
In addition, the identification of one case of heavy metal
toxicity of a user of non-conventional medicines should be
considered presumptive evidence of additional unidentified
cases of toxicity and should trigger additional investigation.
Case presentation
A 69 year old Caucasian male retired lawyer presented for
evaluation of lethargy, fatigue, memory impairment, gener-
alized weakness, severe constipation, anorexia, and weight
loss of 18 kg over the preceding eight months. Approxi-
mately six weeks before the onset of his symptoms, he
began using an Ayurvedic herbal medication, “Bhasma”,
which he obtained while traveling in India. The medication
was used to treat partial aphasia, cognitive impairment,
and right-sided motor weakness resulting from a spontan-
eous left temporoparietal hemorrhagic stroke experienced
two years previously.
Prior to presentation at our hospital, the patient had
been admitted to another facility for evaluation of his
symptoms and was found to have a hemoglobin level of
6.4 gm/dL (reference range: 13.2 gm/dL – 17.7 gm/dL).
CT scan of the abdomen and pelvis, upper endoscopy and
colonoscopy revealed no etiology for his anemia at that
hospital. Subsequent to starting the Bhasma, the patient
was also treated with citalopram (a selective serotonin re-
uptake inhibitor antidepressant) for depressed mood. He
had no prior psychiatric history nor tendency toward de-
pressed mood.
On further laboratory evaluation, a blood lead level (BLL)
of 94 μg/dL (reference range: 0.0-4.9 μg/dL) was obtained.
After the family suggested the Ayurvedic “Bhasma” medica-
tion could be the cause, it was analyzed for heavy metals
and found to contain 19,400 mg/kg of lead and 1,430 mg/
kg of arsenic. At the recommendation of the Iowa Poison
Control Center, he was admitted to the medical intensive
care unit for monitoring, given intramuscular chelation
with Dimercaprol (BAL) at a dose of 5 mg/kg q4 hrs for
three days, and given intravenous chelation with calcium
disodium EDTA at a dose of 1500 mg/m2/day as a continu-
ous infusion for five days beginning after the second doseof BAL. While in the ICU, he was monitored with daily
labs including a CBC with differential, electrolyte panel in-
cluding BUN and creatinine, calcium, phosphorous, mag-
nesium, alkaline phosphatase, AST, ALT, glucose, and
urinalysis. The patient’s blood lead level following two
days of chelation with BAL and EDTA as described above
had dropped to 27.1 μg/dL.
After six days, the patient was discharged from the hos-
pital. His blood lead level on discharge was 25.5 μg/dL
and he was instructed to complete a nineteen day course
of oral chelation with dimercaptosuccinic acid (DMSA),
10 mg/kg three times daily for five days, then 10 mg/kg
twice daily for fourteen days.
After completion of the nineteen day course of DMSA,
the patient’s BLL had decreased to 23 μg/dL and he
reported feeling much more energetic. Over the next six
weeks his BLL rose to 38 μg/dL and the patient reported a
coincident decline in speech fluency and memory. Add-
itional chelation was recommended and he was treated
with another course of oral DMSA which reduced his BLL
to 20 μg/dL. The patient again reported that his mood was
much improved and he then discontinued use of anti-
depressant medication without recurrence of depressed
mood. Three months later, he received an alternative
treatment at an Ayurvedic Health Clinic due to continued
symptoms of cognitive impairment. The alternative treat-
ment consisted of thirteen days of “Bastis” (enemas) and
oil massages which were intended to rid his body of lead.
Six months after initial diagnosis and after having com-
pleted four courses of chelation therapy and an alternative
treatment, the patient and his wife reported that he had
persistent difficulty with “mental focus and clarity” in
comparison to his post-stroke baseline. Repeat BLL was
29 μg/dL at that time. Although not typically offered to pa-
tients with a BLL below 40 μg/dL, a third nineteen day
course of oral DMSA chelation therapy was administered
in an effort to treat the patient’s cognitive symptoms. His
blood lead level following the third course of chelation
with DMSA was 7 μg/dL. Neuropsychological testing was
performed both before and immediately following com-
pletion of the third course of DMSA to assist in
distinguishing reversible neurocognitive effects of lead
from fixed residual effects of his prior stroke. His clinical
presentation was most notable for dysfluent aphasia refer-
able to his cerebrovascular accident in 2009. Impairments
were found in aspects of language, working memory/ex-
ecutive functions, and right-sided fine motor dexterity.
He was oriented to time, personal information, and place.
Working memory for digit sequences and geometric
figures was low average to average. Visual processing
speed was average for symbol discrimination and coding
tasks. Speeded visuomotor sequencing was average under
focused attention, but mildly impaired under divided
attention. Verbal sequencing was borderline impaired.
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coordination was moderately impaired for dominant right hand
and borderline impaired for non-dominant left hand.
The post chelation test showed “modest performance
gains across various tests of attention and cognitive effi-
ciency”. Specifically his performance on the Controlled Oral
Word Association Test revealed a doubling of his raw score
from 11 to 22 reflecting a significant improvement in se-
mantic and phonetic verbal fluency. In addition his per-
formance on the Wechsler Adult Intelligence Scale test
revealed more than doubling of the Digit Span score from
3 to 7 and more modest improvements in the Symbol
Search and Coding scores from 7 to 9 and 8 to 10, respect-
ively. Although it is possible that practice effects contrib-
uted to the observed improvement, the patient reported a
reduction in fatigue and greater clarity of his thinking after
this third course of DMSA chelation suggesting at the least
subjective clinical improvement.
Discussion
This patient’s illness raises several issues relevant to en-
vironmental health specialists, clinical toxicologists and
occupational health physicians who provide services to in-
dividuals and populations at risk of lead exposure from oc-
cupational or environmental exposures such as imported
traditional or alternative herbal products or medicinal
agents. These issues include contamination of alternative
agents with metals and other toxicants, cognitive and
affective benefits of treatment of lead toxicity among adult
patients, and the risks and potential benefits of multiple
chelation treatments.
Clinical manifestations of adult lead toxicity
Adult lead toxicity can be categorized as either acute or
chronic. Acute lead toxicity results from short-term, high
dose lead absorption. Signs and symptoms often include
normocytic or microcytic anemia, abdominal pain and
constipation (“lead colic”), arthralgias and myalgias, and
central nervous system impairment including headache,
mood disorder and encephalopathy and can occur within
weeks of the onset of sufficient exposure [7,9]. Chronic
toxicity from lower doses of lead absorbed over longer du-
rations results in more gradual increase in body burden
and more variable symptoms, including decreased libido,
impotence, infertility, anorexia, abdominal pain, weight
loss, change in bowel habits, muscle weakness and pain, fa-
tigue, depression, irritability, insomnia, paresthesias, head-
ache, and nervousness [10], some of which were reported
by our patient. Dose-related effects of lead on multiple
organ systems have been described, including hematologic
abnormalities such as normocytic or microcytic anemia,
neurologic effects including peripheral nerve dysfunction
and encephalopathy, renal toxicity including interstitial
nephritis and elevated blood pressure, and reproductivedysfunction such as infertility and elevated miscarriage
rates [8].
Our patient manifested many of the known symptoms
and signs of acute lead toxicity, including anemia, abdom-
inal pain and constipation, altered affect, and neuro-
cognitive impairment [11]. Given onset of symptoms six
weeks after initiating Ayurvedic treatment, he likely expe-
rienced relatively rapid increase in blood lead levels. As
expected, his blood lead levels decreased immediately fol-
lowing chelation therapy and showed some rebound after
completion of treatment suggesting re-distribution from
bone.
Risks and benefits of chelation treatment
In the current era, the most commonly recommended
agents for chelation of lead are calcium-disodium EDTA
and DMSA. DMSA has the advantage of enteral adminis-
tration whereas EDTA is routinely administered intraven-
ously. While chelation with either agent is considered
relatively safe [12], known side effects of each should be
considered prior to administering treatment. Adverse ef-
fects of DMSA therapy include elevation of hepatic trans-
aminases and mucocutaneous and skin reactions [13].
While moderate elevation of hepatic transaminases are
not considered a contraindication to initiation of chelation
with DMSA [13], the risks and benefits of chelation in the
presence of liver disease or prior DMSA-related skin reac-
tions should be considered when choosing a chelating
agent. Persons with glucose-6-phosphate dehydrogenase
deficiency should not receive DMSA as the drug has been
reported to cause hemolytic anemia in these patients [14].
Further, DMSA has been shown to produce both de-
creased maternal weight gain and fetotoxicity in experi-
mental studies [13]. Although these effects were produced
at higher doses than are used clinically, IV EDTA is gener-
ally considered a safer alternative if chelation is necessary
during pregnancy.
The most serious side effect of EDTA chelation is dose-
dependent nephrotoxicity [15] and close monitoring of
renal function should be performed routinely in patients
undergoing EDTA therapy. While skin reactions have also
been described with use of EDTA, it is hypothesized that
these mild reactions are due to zinc deficiency resulting
from chelation rather than an allergic reaction [15].
Chelation decisions are complicated by the fact that
symptoms of lead toxicity are variable and do not consist-
ently associate with observed blood lead levels. Adults with
characteristic symptoms and substantially elevated blood
lead levels typically report symptomatic improvement fol-
lowing chelation therapy. Furthermore, chelation is espe-
cially recommended among persons with elevated blood
lead levels and altered mental status suggestive of enceph-
alopathy [12]. However, evidence for chelation is sparse for
adult patients with blood lead levels below 30 μg/dL,
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with blood lead levels above 30 μg/dL. In this setting of un-
certainty, we elected to chelate the case patient when his
BLL was 29 μg/dL in an effort to more fully control his
neurocognitive and affective symptoms. One consideration
was the potential that his symptoms and cognitive impair-
ment were residual from his prior CVA and would not be
responsive to additional chelation. However, this patient
provided a clear history of greater cognitive symptoms fol-
lowing use of the Ayurvedic medication in comparison to
his post stroke (but pre-medication) baseline, suggestive of
a toxic etiology.
We based the decision to chelate on epidemiological evi-
dence associating relatively low BLLs to adverse cognitive
effects and a small number of case reports of improve-
ments in cognitive and affective symptoms following che-
lation therapy among patients with low blood lead levels.
Adverse neurocognitive effects among adults with BLLs
below 40 μg/dL have been described [16-19]. Epidemio-
logic evidence of decrements in cognitive function among
adults has been reported for mean blood lead levels of
4.5 μg/dL [20]. Thus, it is plausible that the case patient’s
symptoms and cognitive impairments were, at least in
part, related to lead exposure.
In addition to epidemiological evidence of neurological
effects at low BLLs, apparent reversibility of cognitive im-
pairment at low BLLs has been reported in several case re-
ports. Linz et al. [21] described the effects of chelation
treatment of a 37 year old construction worker with a BLL
of 16 μg/dL. One year prior, he had a BLL of 109 μg/dL
which decreased spontaneously after removal from expos-
ure. Despite his BLL reduction, he reported persistent
symptoms of short term memory loss, insomnia, fatigue,
weakness and depression. Neuropsychological testing was
administered before and following chelation with EDTA.
Mild to moderate improvement was noted on tests of ver-
bal fluency, visual motor speed, and overall memory. In
addition, a standard test of depression showed improve-
ment. Frumkin and Gerr [22] reported a substantial im-
provement in mood in a lead battery plant worker
following chelation with DMSA. The patient had been
given a diagnosis of major depression and was treated with
fluoxetine. The patient’s BLL was 26 μg/dL immediately
prior to chelation and was 12 μg/dL following chelation.
The patient was able to discontinue fluoxetine after treat-
ment and reported improvement in mood, increased rest-
fulness of sleep, and reduction in irritability.
Clearly, the evidence base is limited regarding treatment
of patients with modest elevations in BLL and persistent
neurocognitive complaints. Treatment decisions should be
made using the best available evidence, individualized to
the patient’s symptoms and situation, and in consultation
with the patient. In the case presented here, the patient
was frustrated by his ongoing cognitive difficulties and alsoreported a strong desire to discontinue use of antidepres-
sant medication. The relatively small risk of adverse events
from a third course of DMSA chelation was outweighed by
the possibility of improved mood and cognitive perform-
ance. His cognitive function improved following treatment
and his symptoms of depression resolved completely, as
described previously [22,23].
Conclusions
The workplace is the most common source of adult lead
exposure. However, non-occupational sources of lead
must be considered among patients with characteristic
signs and symptoms of lead toxicity and no known occu-
pational exposure. It is axiomatic that effective manage-
ment of lead toxicity requires identification and mitigation
of the exposure.
The case presented here raises concern that the ready
availability of unregulated domestic and foreign herbal
medications and supplements is a potential public health
hazard. A 2007 National Health Interview Survey found
that 38% of adults in the U.S. use complementary and al-
ternative therapies [24]. Despite this widespread use, the
alternative medicine industry is, essentially, self-regulating
and without federal enforcement. Recommendations have
been made by the U.S. Food and Drug Administration that
manufacturers of supplements sold in the U.S. conform to
“Good Manufacturing Practices” [25], but this case report
as well as others demonstrates that more regulation is ne-
cessary to ensure the safety of persons consuming these
therapies. The sentinel case presented here has led to an
ongoing investigation by state public health authorities of
other users of Ayurvedic supplements.
Another question raised by this case is that of when and
whether chelation is likely to benefit adult patients with
modest elevations of BLL. We know of no consensus
guidelines for administration of chelation therapy to such
adults. The case presented here illustrates the potential
benefit of chelation on cognitive function among chronic-
ally exposed adults, but provides no definitive guidance. A
sufficiently large intervention study of the benefits of chela-
tion on cognitive impairment (and other adverse effects of
lead) among patients with modestly elevated BLLs would
be useful to clinicians. A risk-benefit analysis incorporating
the known adverse effects of chelation therapy, improve-
ments in subclinical cognitive function attributable to low-
ering body lead burdens, and the cost of chelation therapy
would support evidence-based guidelines for management
of mild to moderate elevations of BLL among adults.
An important lesson learned from this case is that pre-
vention, recognition, and treatment of lead toxicity requires
a high index of suspicion. Both allopathic and alternative
medicine practitioners and public health specialists need to
be aware of the widespread use of herbal and alternative
therapies and the potential for contamination of and side
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dent in this case, concomitant use of alternative remedies
with traditional pharmacologic medications could produce
previously unknown adverse interactions. Recognizing that
no therapeutic agent ingested by humans can be considered
completely “safe”, and that both risks and benefits should
be considered, is an important lesson for both practitioners
and patients, alike.
Consent
Written informed consent was obtained from the patient
for publication of this case report. A copy of the written
consent is available for review by the Editor-in-Chief of
this journal.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LF facilitated blood lead testing and chelation for the patient. LF and LB
participated in follow-up care for the patient. All authors collaborated in drafting
the manuscript. All authors have read and approved the final manuscript.
Acknowledgements
Dr. Harold Adams and Dr. Robert Jones
Laura Breeher is no longer affiliated with the University of Iowa, but this
article was written while at the University of Iowa.
Author details
1Department of Occupational Medicine, Mayo Clinic Health System, 1025
Marsh St, Mankato, MN 56001, USA. 2Department of Occupational and
Environmental Health, College of Public Health, The University of Iowa, 105
River Street, Iowa City, IA 52242, USA. 3Occupational and Environmental
Health and Internal Medicine, College of Public Health, The University of
Iowa, 2207 Westlawn Bldg, Iowa City, IA 52242, USA.
Received: 17 April 2013 Accepted: 16 September 2013
Published: 2 October 2013
References
1. Saper RB, Phillips RS, Sehgal A, Khouri N, Davis RB, Paquin J, Thuppil V, Kales
SN: Lead, mercury, and arsenic in US- and Indian-manufactured
Ayurvedic medicines sold via the Internet. JAMA 2008, 300(8):915–923.
2. Saper RB, Kales SN, Paquin J, Burns MJ, Eisenberg DM, Davis RB, Phillips RS:
Heavy metal content of ayurvedic herbal medicine products. JAMA 2004,
292:2868–73.
3. Thatte UM, Rege NN, Phatak SD, Dahanukar SA: The flip side of Ayurveda.
J Postgrad Med 1993, 39:179–82.
4. CDC: Poisoning Associated with Ayurvedic Medications – Five States,
2000—2003. MMWR 2004, 53:582–584.
5. Raviraja A, Vishal Babu GN, Sehgal A, Saper RB, Jayawardene I,
Amarasiriwardena CJ, Venkatesh T: Three cases of lead toxicity associated
with consumption of ayurvedic medicines. Indian J Clin Biochem 2010,
25(3):326–9.
6. van Schalkwyk J, Davidson J, Palmer B, Hope V: Ayurvedic medicine:
patients in peril from plumbism. N Z Med J 2006, 119(1233):U1958.
7. CDC: Adult Blood lead epidemiology and surveillance - United States,
2008–2009. MMWR 2011, 60(25):841–5.
8. Exposure to lead: A major public health concern. WHO; 2010. http://www.
who.int/ipcs/features/lead.pdf.
9. Levin SM, Goldberg M: Clinical evaluation and management of lead-
exposed construction workers. Am J Ind Med 2000, 37(1):23–43.
10. Cullen MR, Robins JM, Eskenazi B: Adult inorganic lead intoxication:
presentation of 31 new cases and a review of recent advances in the
literature. Medicine 1983, 62(4):221–47.
11. Lead: ATSDR (Agency for Toxic Substances and Disease Registry); 2011.http:/
www.atsdr/cdc/gov.12. Kosnett MJ: Chelation for heavy metals (arsenic, lead, and mercury):
protective or perilous? Clin Pharmacol Ther 2010, 88:412–415.
13. Bradberry S, Vale A: Dimercaptosuccinic acid (succimer; DMSA) in
inorganic lead poisoning. Clin Toxicol 2009, 47(7):617–631.
14. Gerr F, Frumkin H, Hodgins P: Hemolytic anemia following succimer
administration in a glucose-6-phosphate dehydrogenase deficient
patient. J Toxicol Clin Toxicol 1994, 32(5):569–575.
15. Bradberry S, Vale A: A comparison of sodium calcium edetate (edetate
calcium disodium) and succimer (DMSA) in the treatment of inorganic
lead poisoning. Clin Toxicol 2009, 47(9):841–858.
16. Barth A, Schaffer AW, Osterode W, Winker R, Konnaris C, Valic E, Wolf C,
Rüdiger HW: Reduced cognitive abilities in lead-exposed men. Int Arch
Occup Environ Health 2002, 75(6):394–8.
17. Kosnett MJ, Wedeen RP, Rothenberg SJ, Hipkins KL, Materna BL, Schwartz
BS, Hu H, Woolf A: Recommendations for medical management of adult
lead exposure. Environ Health Perspect 2007, 115(3):463–71.
18. Payton M, Riggs KM, Spiro A, Weiss ST, Hu H: Relations of bone and blood
lead to cognitive function: the VA Normative Aging Study.
Neurotoxicol Teratol 1998, 20(1):19–27.
19. Shih RA, Hu H, Weisskopf MG, Schwartz BS: Cumulative lead dose and
cognitive function in adults: a review of studies that measured both
blood lead and bone lead. Environ Health Perspect 2007, 115(3):483–92.
20. Wright RO, Tsaih SW, Schwartz J, Spiro A, McDonald K, Weiss ST, Hu H: Lead
exposure biomarkers and mini-mental status exam scores in older men.
Epidemiology 2003, 14(6):713–8.
21. Linz DH, Barrett ET Jr, Pflaumer JE, Keith RE: Neuropsychological and
postural sway improvement after Ca(++)-EDTA chelation for mild lead
intoxication. J Occup Med 1992, 34(6):638–641.
22. Frumkin H, Gerr F: Dimercaptosuccinic acid in the treatment of
depression following lead exposure. Am J Ind Med 1993, 24(6):701–6.
23. Schottenfeld RS, Cullen MR: Organic affective illness associated with lead
intoxication. Am J Psychiatry 1984, 141(11):1423–6.
24. Nahin RL, Barnes PM, Stussman BJ, Bloom B: Costs of Complementary and
Alternative Medicine (CAM) and Frequency of Visits to CAM
Practitioners: United States, 2007. In National health statistics reports.
Hyattsville, MD: National Center for Health Statistics; 2009:1–14 (18).
25. AHPA (American Herbal Products Association): Heavy metal analysis and
interim recommended limits for botanical dietary supplements: White Paper.
Silver Spring, MD: AHPA; 2009.
doi:10.1186/1745-6673-8-26
Cite this article as: Breeher et al.: A case report of adult lead toxicity
following use of Ayurvedic herbal medication. Journal of Occupational
Medicine and Toxicology 2013 8:26.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
